[1] Richelson, E. (1999) J. Clin. Psychiatry, 60(Suppl 10), 5.
[2] Caley, C.F. and Rosenbaum, S. (1998) Formulary, 33, 105.
[3] Proceedings of International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), Tripartite harmonised guideline Q3C Impurities: Residual Solvent’s, 1997.
[4] The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use, ICH Topic Q3C (M) Maintenance of Note for guidance on Impurities: Residual solvents (CPMP/ICH/283/95), Permissible Daily Exposure (PDE) for Tetrahydrofuran and N-Methylpyrrolidone?.
[5] Proceedings of International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), Tripartite harmonised guideline Q3A (R) Impurities in new drug substances?, 2002.
[6] Residual solvents (5.4), European Pharmacopoeia, Supplement 4.6., Directorate for the Quality of Medicines of the Council of Europe, Strasbourg, fourth ed., p. 3911, 2004.